The CMS has finalized the first cycle of drug price negotiations under the IRA, establishing precedent for improved ...

A promising “two-in-one” experimental drug could tackle both type 2 diabetes and heart disease by slashing cholesterol and ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Hospitalized patients with diabetes require specialized management to reduce readmission rates and complications. Newer ...

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, officially becoming the world’s best-selling drug. Lilly is working to shore ...

Building on earlier studies showing its benefits for type 2 diabetes, a new study has revealed the experimental drug IC7Fc ...

Beginning in 2026, Medicare will lower costs on 10 high-priced drugs through negotiated pricing, making medications more affordable for seniors.

Empagliflozin and nasal insulin spray both improved memory, brain health and blood flow among people with early Alzheimer’s disease or mild cognitive impairment ...

A well-established diabetes drug alleviated brain inflammation in a female mouse model of multiple sclerosis, suggesting the long-used medicine could be repurposed to combat MS in people with female ...